AzTrials
AzTrials

Uterine FibroidsNCT00163930

Post-Operative Pain Management in Patients Undergoing Uterine Artery Embolisation for Symptomatic Leiomyomata

An observational study of Uterine Fibroids, run by Bayside Health at 1 site in Australia.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

This project seeks to evaluate the effectiveness of a new post-operative pain relief program for women who have undergone uterine artery embolisation (UAE). UAE is performed by an interventional radiologist as a treatment of uterine fibroids (non-cancerous growths of the uterus.) UAE can be associated with a high… Read more about this study

Who is it for?
Ages 18 to 80 years, women only
Conditions the study is for
Uterine Fibroids
How many people
Not given
Where
1 siteAustralia
Study dates
Jan 2005to Dec 2007
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • na

Who cannot join

  • na

Trial locations and contacts

1 site in 1 country.

Kenneth Thomson, MBBS RANZCR contact

613 9276 2000 ext. 3606

k.thomson@alfred.org.au

Australia1 site, 1 recruiting
  • Radiology Department, The Alfred

    Melbourne, Victoria, 3004

    Helen Kavnoudias, PhD, 61 3 9276 2000 ext. 3606, h.kavnoudias@alfred.org.au

    Kenneth Thomson, MBBS RANZCR

    Recruiting

Other trials in Australia

About this study

This project seeks to evaluate the effectiveness of a new post-operative pain relief program for women who have undergone uterine artery embolisation (UAE).

UAE is performed by an interventional radiologist as a treatment of uterine fibroids (non-cancerous growths of the uterus.) UAE can be associated with a high level of post-procedural pain and it is the purpose of this study to evaluate a new relief regimen for dealing with this acute pain.

Read more

There will be two treatment groups into which patients will be randomly assigned. One will receive the current post-operative therapy (dose-on-demand) and the other will receive the new therapy (pre-emptive dosing). Otherwise patients will receive standard management protocol for this procedure. Only patients that are scheduled for UAE will be enrolled (up to 40 patients).

The new treatment involves giving the patient their morphine dose orally and sixty minutes before the procedure begins (pre-emptive dosing) as opposed to current standard treatment which involves giving the patient a dose of morphine intravenously once they feel pain.

Information to be collected directly from patients includes pain and nausea levels, indicated on a visual scale (a 10 centimetre line showing a spectrum of no pain to worst pain imaginable) as well as their opinions of the effectiveness of the pain relief program and the procedure itself. This information is to be collected immediately post-procedure and at 2, 4, 6 and 24 hours post procedure. Each VAS will take the patient approximately 20 seconds to complete. Information about concurrent medication and procedure complications, post-operative vomiting and respiratory depression will be collected from the patient's history.

Read the detailed description

Post operative Pain Management in Paitents Undergoing Uterine Artery Embolisation for Symptomatic Leiomyomata

Protocol (Ver 2.1)

1.1 Research Question Does pre emptive morphine dosing help reduce acute post operative pain (as expressed on a visual analogue scale, VAS) and/or post operative opioid use in patients undergoing uterine artery embolisation?

2.1 Enrolment Patients are enrolled by Prof Ken Thomson or Dr Stuart Lyon during a planning consultation with each woman. They will be required to sign a consent form if they choose to participate at this point. 3 photocopies of this consent form will be taken, with one copy to go with: the patient; the history; and the data file.

2.2 Exclusions

Patients with the following should be excluded from the study:

  • Pregnancy
  • Contrast allergy
  • Allergy to one or more of the treatment drugs
  • History of alcoholism
  • Diagnosed hepatic disease
  • Renal insufficiency
  • Acute pelvic infection
  • Endometrial carcinoma
  • Undiagnosed pelvic mass
  • Non English speaking patients
  • Patients who require post op non opioid analgesia

3.1 Randomisation and blinding The placebo and oxycontinSR tablets have been pre randomised by the clinical trials pharmacy on LG level (Ann Mak).

4.1 Pre medications The trial drug (oxycontin) will be ordered on a yellow clinical trial prescription form. A day before the patient arrives, this form should be faxed to the Clinical Trials Pharmacy (Fax No 3305). A registered nurse from the ward or researcher should then pick up the drugs from the Clinical Trials Pharmacy on LG level.

The other non trial medications should be either already on the ward or should be ordered via pharmacy as per normal.

The trial drugs and pre medications will all be written up on a prepared drug chart which will be given to the ward.

4.2 Treatment

The ward staff will administer the drugs as prescribed on the drug chart 60 +/- 20 minutes prior to the procedure.

The differences in the treatment is shown on the following table. Dose on demand treatment Pre emptive treatment

1 hour before surgery:

  • Paracetamol 1.5g
  • Temazepam 20mg
  • Placebo OxycontinSR
  • Piroxicam (Feldene) 20mg
  • Ondansetron 8mg 1 hour before surgery:
  • Paracetamol 1.5g
  • Temazepam 20mg
  • OxycontinSR
  • Piroxicam (Feldene) 20mg
  • Ondansetron 8mg

Surgery:

  • PCA morphine
  • 1mg dose with 5 minute lockout Surgery:
  • PCA morphine
  • 1mg dose with 5 minute lockout Follow up
  • Endone 5-10mg oral 4/24 prn Follow up
  • Endone 5-10mg oral 4/24 prn

The ward staff will be blinded as to which treatment the patient receives since the pre meds are have been randomised and blinded by the pharmacy.

5.1 Post op Pain and nausea measurements will be taken at 2, 4, 6 and 24 hours using the visual analogue scale (VAS) questionnaire sheets. This can be done either by the researchers, or if time permits, ward staff.

Drug related side effects are also recorded, such as respiratory depression and vomiting and it is therefore important for these to be carefully documented in the patient's history.

5.2 Deviations from pain management protocol There may be instances where the PCA does not deliver adequate pain relief. It may be necessary in these cases to deviate from the pain management protocol for the comfort of the patient. This does not necessarily exclude the patient from the study. However, the way in which the data is interpreted once non opioid analgesia is given should be done with caution.

Deviations should be instituted when:

  • Obvious drug related side effects are evident (e.g. respiratory depression, narcosis); or
  • Pain is not at an acceptable level at 6 hours post procedure; or
  • Pain is not at a level in keeping with routine post UAE pain as reported by nursing or medical staff.

Please notify Dr Stuart Lyon or Dr Jeff Tam (ex 3606) if the Pain Team needs to intervene for these patients. They will then assess whether or not the patient will be excluded from the study.

6.1 Discharge

When patients are deemed ready for discharge they need to take home a discharge pack with some questionnaires for them to fill out at home. These should be done at 24 hours post procedure. The pack will include:

  • Pain VAS
  • Nausea VAS
  • Overall pain relief rating VAS
  • UAE procedure rating VAS
  • Instructions sheet
  • Reply paid, self addressed envelope

Please check that the 2, 4 and 6 hour questionnaires have been filled out before the patient is discharged, and that they leave with the discharge pack. Once completed, the questionnaires should be sent back to the Radiology Research Department.

Most patients will be discharged within 24 hours of the procedure. In the event that the patient stays in hospital longer than 24 hours, then the discharge pack should be completed at the 24 hour mark. The completed data sheets should then be sent back to the Radiology Research Department.

If the data sheets are not received within 2 weeks of discharge, the researchers should make a phone call to the patient to enquire whether they have been completed and to answer any questions the patient may have.

Keywords
Uterine Fibroids, embolisation, pain management
Medical subject headings
Leiomyoma, Agnosia

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Sep 2005 (estimated)
  2. Study startJan 2005
  3. Study completionDec 2007

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Defined population
Time perspective
Other
IDs, dates and publications
ClinicalTrials.gov ID
NCT00163930
Sponsor's protocol ID
AlfRad2004-1
Status last verified
Sep 2005
First submitted
12 Sep 2005
Last updated
3 Oct 2006
Results posted
No

Publications

  • Konstantatos AH, Kavnoudias H, Stegeman JR, Boyd D, Street M, Bailey M, Lyon SM, Thomson KR. A randomized, double-blind, placebo-controlled study of preemptive oral oxycodone with morphine patient-controlled anesthesia for postoperative pain management in patients undergoing uterine artery embolization for symptomatic uterine fibroids. Cardiovasc Intervent Radiol. 2014 Oct;37(5):1191-7. doi: 10.1007/s00270-014-0913-2. Epub 2014 Jul 1.

    PubMed 24981461

Questions about this trial

What is this clinical trial studying?

An observational study of Uterine Fibroids, run by Bayside Health at 1 site in Australia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 3 Oct 2006. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kenneth Thomson, MBBS RANZCR (613 9276 2000 ext. 3606, k.thomson@alfred.org.au), or a site near the patient. AzTrials does not enrol participants or take referrals.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00163930, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Oct 2006.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in